ReShape Lifesciences Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

HIND$1.59+0.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

** **(in thousands, except share and per share amounts)


· · December 31, · · December 31,
	2023		2022
ASSETS
Current assets:
Cash and cash equivalents		$4,459		$3,855
Restricted cash		100		100
Accounts and other receivables (net of allowance for doubtful accounts of $804 and $410 respectively)		1,659		2,180
Inventory		3,741		3,611
Prepaid expenses and other current assets		337		165
Total current assets		10,296		9,911
Property and equipment, net		60		698
Operating lease right-of-use assets		250		171
Deferred tax asset, net		28		56
Other intangible assets, net		—		260
Other assets		29		46
Total assets		$10,663		$11,142
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$1,689		$1,926
Accrued and other liabilities		1,814		5,040
Warranty liability, current		163		344
Operating lease liabilities, current		111		171
Total current liabilities		3,777		7,481
Operating lease liabilities, noncurrent		151		—
Common stock warrant liability		72		—
Total liabilities		4,000		7,481
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, 10,000,000 shares authorized:
Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at December 31, 2023 and December 31, 2022		—		—
Common stock, $0.001 par value; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 23,457,047 and 519,219 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively		23		1
Additional paid-in capital		642,302		627,935
Accumulated deficit		(635,574)		(624,187)
Accumulated other comprehensive loss		(88)		(88)
Total stockholders’ equity		6,663		3,661
Total liabilities and stockholders’ equity		$10,663		$11,142

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.